10-K: MiNK Therapeutics Reports 2025 Results, Advances iNKT Pipeline

MiNK Therapeutics reported increased net losses and a going concern warning in its 2025 annual report, while highlighting promising clinical progress for its lead iNKT cell therapy, agenT-797, in oncology and pulmonary diseases.

Summary

• MiNK Therapeutics is focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
• The lead product candidate, agenT-797, is in Phase 2 clinical development for critical pulmonary immune failure (severe pneumonia and moderate-to-severe acute hypoxemic respiratory failure) and refractory solid tumor cancers.
• Phase 1/2 data for agenT-797 in mechanically ventilated patients with severe viral ARDS showed >70% 30-day survival (80% in the VV-ECMO subgroup) compared to ~10% in contemporaneous controls.
• Phase 1 clinical trial data for agenT-797 in 34 patients with refractory solid tumors demonstrated durable clinical activity, including complete remissions and long-term survivors (>23+ years), with a median overall survival of approximately 23 months in combination with anti-PD-1.
• Case reports published in Oncogene (January 2024 and 2025) detailed a durable partial response in gastric cancer and a complete remission in metastatic testicular cancer following agenT-797 treatment.
• A Phase 2 investigator-sponsored trial for agenT-797 in combination with Agenus' botensilimab and balstilimab, plus ramucirumab and paclitaxel, for advanced esophageal, gastric, or GEJ adenocarcinoma, initiated in February 2024.
• Early translational data from the Phase 2 combination study (AACR IO 2025) showed robust immune activation, including elevated interferon-gamma levels, rapid tumor infiltration, CD8+ T-cell activation, and immune reprogramming.
• Preclinical engineered iNKT programs, MiNK-413 (BCMA-CAR-iNKT) and MiNK-215 (FAP-CAR-iNKT), are advancing, with IND-enabling studies underway for MiNK-215.
• The company reported a net loss of $12.5 million for the year ended December 31, 2025, compared to $10.8 million in 2024.
• An accumulated deficit of $156.7 million was reported as of December 31, 2025.
• Cash and cash equivalents stood at $13.4 million as of December 31, 2025.
• The independent registered public accounting firm included an explanatory paragraph regarding the company's ability to continue as a going concern.
• The company raised $17.5 million in net proceeds from an At Market Issuance Sales Agreement in 2025 and an additional $3.0 million from January 1, 2026, through March 27, 2026.
• A $5.0 million related party note, plus accrued interest of $179,444, was repaid in full in January 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While clinical data for agenT-797 shows promising efficacy in severe conditions, the increasing net loss, significant accumulated deficit, and explicit going concern warning indicate substantial financial challenges and high operational risk.

Positives

• AgenT-797 demonstrated promising Phase 1/2 data in severe viral ARDS, showing >70% 30-day survival (80% in VV-ECMO subgroup) compared to ~10% in contemporaneous controls.
• Durable clinical activity, including complete remissions and long-term survivors (>23+ years), was observed in heavily pretreated, checkpoint-refractory solid tumors with agenT-797, achieving a median overall survival of approximately 23 months in combination with anti-PD-1.
• AgenT-797 exhibited long-term persistence in peripheral blood (up to 6 months post-infusion) without requiring HLA matching or lymphodepletion.
• Early translational data from the Phase 2 combination study showed robust immune activation, including elevated interferon-gamma levels, rapid tumor infiltration, CD8+ T-cell activation, and immune reprogramming in PD-1-refractory gastroesophageal cancers.
• Advancing a pipeline of next-generation engineered iNKT programs, MiNK-413 and MiNK-215, with IND-enabling studies underway for MiNK-215.
• Vertically integrated manufacturing capabilities are designed for scalability, reduced cost of goods, and increased production flexibility and speed.
• Strategic collaborations with Agenus, C-Further, Autonomous Therapeutics, and Immunoscape are in place to enhance platform value and expand technological capabilities, pipeline breadth, or clinical impact.
• The company regained compliance with Nasdaq's Minimum Value of Listed Securities (MVLS) rule in July 2025.

Negatives

• The company incurred a net loss of $12.5 million for the year ended December 31, 2025, an increase from $10.8 million in 2024.
• An accumulated deficit of $156.7 million was reported as of December 31, 2025.
• The independent registered public accounting firm included an explanatory paragraph in its report relating to the company's ability to continue as a going concern.
• The business is highly dependent on the success of agenT-797, which is the only product candidate currently in clinical development, with all other candidates in preclinical stages.
• Research and development (R&D) expense decreased by 9% to $5.8 million in 2025 from $6.3 million in 2024, potentially indicating reduced investment in pipeline expansion.
• General and administrative (G&A) expense increased by 56% to $6.7 million in 2025 from $4.3 million in 2024, primarily due to professional fees and share-based compensation.
• The company will need substantial additional funding to continue operations, and the completion of anticipated funding is not entirely within its control.
• Agenus, the company's largest stockholder, now owns less than 50% of the voting power, resulting in the loss of 'Controlled Company' status as defined by Nasdaq rules.

Risks

• Expect to incur losses for the foreseeable future and may never achieve or maintain profitability.
• If unable to raise additional capital, forced to delay, reduce, or eliminate certain projects.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies.
• Short history as an independent company may make it difficult to evaluate business success and future viability.
• Future ability to utilize certain tax attributes may be limited.
• Independent registered public accounting firm included a going concern explanatory paragraph in its report on audited financial statements.
• Business is highly dependent on the success of lead product candidate, agenT-797, and may fail to develop it successfully or obtain marketing approval.
• Allogeneic iNKT cells represent a novel approach to immunotherapy, which may result in significant challenges to development, marketing approval, and commercialization.
• Product candidates will require significant additional testing before seeking marketing approval.
• Serious adverse events, undesirable side effects, or unexpected characteristics caused by product candidates could delay or prevent marketing approval, limit commercial potential, or result in significant negative consequences following any potential marketing approval.
• Data produced in clinical trials is at an early stage and future data may not show responses in patients treated or support continued development.
• Even if any product candidates receive marketing approval, they may fail to achieve commercial success.
• Significant competition exists, and competitors may achieve marketing approval before the company or develop adoptive cell therapies that are safer, more advanced, or more effective.
• Any product candidates developed may be complex and difficult to manufacture.
• Clinical trials failing to demonstrate safety and efficacy may incur additional costs or experience delays.
• Delays or difficulties in the enrollment of patients in clinical trials.
• The regulatory landscape governing any product candidates is uncertain and may change.
• Any failure to comply with laws and regulations could expose the company to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits.
• Healthcare and other reform legislation may increase the difficulty and cost to obtain marketing approval and commercialize product candidates.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities.
• Laws and regulations governing international operations may preclude developing, manufacturing, and selling certain product candidates outside the United States and require costly compliance programs.
• Subject to stringent privacy and information security laws, regulations, policies, and contractual obligations; changes could adversely affect the business.
• Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or policy changes could hinder timely review and approval of new products.
• May experience difficulty in separating resources from Agenus.
• Agenus owns a significant portion of common stock and can exert control over specific matters subject to stockholder approval.
• Certain directors and officers may have actual or potential conflicts of interest because of their positions with Agenus.
• Reliance on third parties for clinical trials and some aspects of research and preclinical testing; these third parties may not perform satisfactorily.
• Reliance on third parties for manufacturing increases the risk of insufficient quantities of materials or product candidates, or availability at an unacceptable cost.
• If unable to establish collaborations, may have to alter development and commercialization plans.
• May be unable to obtain and maintain satisfactory patent and other intellectual property protection, or if the scope is not sufficiently broad, competitors could develop similar products.
• Rights to develop and commercialize cell-based immunotherapies are subject, in part, to terms and conditions of assignments and licenses granted by others, including Agenus.
• Limited foreign intellectual property rights and may not be able to protect intellectual property throughout the world.
• May not be successful in acquiring or in-licensing necessary rights to key technologies or product candidates.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights.
• May not obtain patent term extension (PTE) and data exclusivity for product candidates.
• May be unable to protect the confidentiality of proprietary knowledge.
• May be unable to retain key executives and to attract, retain, and motivate qualified personnel.
• May encounter difficulties in managing growth, which could disrupt operations.
• Internal computer systems, or those of third-party vendors, collaborators, or consultants, may fail or suffer security breaches.
• A market for common stock may not be sustained; risk of delisting from the Nasdaq Capital Market.
• Provisions in organizational documents and Delaware law may have anti-takeover effects.
• Organizational documents designate courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings.
• Sales of substantial amounts of common stock in the public market, or the perception that these sales may occur, could cause the market price to decline.
• Unfavorable global economic conditions, including tariffs and trade policy changes, could adversely affect business.
• Scrutiny on environmental, social, and governance (ESG) initiatives could increase costs, harm reputation, and adversely impact financial results.

Future Outlook

The company expects to incur losses for the foreseeable future and will require substantial additional funding to continue its operations. Plans include continuing clinical and preclinical development of product candidates, seeking marketing approvals, establishing commercial infrastructure, and expanding its intellectual property portfolio. Expenses are anticipated to increase as programs mature. Additional data from the Phase 2 combination study is expected in early 2026.

Management Comments

• "MiNK Therapeutics, Inc. is focused on developing innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T ("iNKT") cells."
• "Our goal is to discover, develop and commercialize novel allogeneic, off-the-shelf, iNKT cell therapies to treat cancer and other immune-mediated diseases with high unmet need."
• "We believe that allogeneic iNKT cells exhibit highly adaptable properties for broad therapeutic development."
• "We believe these data support the potential application of agenT-797 across a broad range of acute and chronic pulmonary diseases, including ILD, representing a significant market opportunity across critical care and pulmonary medicine."
• "With our vertically integrated manufacturing capabilities and experienced team, we are accelerating the development of accessible, off-the-shelf iNKT-based therapies with transformative potential across oncology, critical pulmonary immune failure, and GvHD."
• "We believe current cancer therapy developments indicate that anti-PD-1 and anti-CTLA-4 immuno-oncology antibodies have the potential to become the standard of care for many tumor indications and will form the basis for most, if not all, future combination therapies in cancer."
• "We believe that our cash and cash equivalents balance, plus anticipated additional funding, will be sufficient to satisfy our liquidity requirements for more than one year from when these financial statements were issued."

Industry Context

StockSavvy.ai notes that MiNK Therapeutics operates in the highly competitive and rapidly evolving field of adoptive cell therapies, specifically focusing on iNKT cells, which uniquely bridge innate and adaptive immunity. The broader industry is experiencing a 'renaissance in innate immunity' with surging investment and clinical activity in NK, T, and iNKT-based therapies. MiNK's allogeneic, off-the-shelf approach aims to address manufacturing complexity, toxicity, and logistical constraints often associated with autologous CAR-T cell therapies. The company's strategy to target both oncology and critical pulmonary immune failure positions it uniquely, as many competitors primarily focus on cancer. Collaborations, such as with Agenus for immuno-oncology antibodies, align with the industry trend of developing combination therapies to enhance efficacy.

Comparison to Industry Standards

• MiNK's agenT-797 Phase 1/2 data in severe viral ARDS demonstrated >70% 30-day survival (80% in the VV-ECMO subgroup) compared to approximately 10% in contemporaneous controls, suggesting a significant improvement over current standard of care for this life-threatening condition.
• Preclinical data for MiNK-413 (BCMA-CAR-iNKT) showed tumor clearance and improved persistence, along with manufacturing and logistical improvements over existing BCMA cell therapies, such as autologous CAR-T products like Abecma (idecabtagene vicleucel) from Bristol Myers Squibb/Celgene and Carvykti (ciltacabtagene autoleucel) from Johnson & Johnson/Legend Biotech.
• MiNK-215 (FAP-CAR-iNKT) reported therapeutic activity in non-small cell lung cancer models, resulting in substantial tumor elimination and improved survival compared to T cells alone, indicating potential superiority to generic T-cell approaches.
• The company's allogeneic, off-the-shelf iNKT cell platform aims to overcome manufacturing complexity, toxicity, and logistical constraints often associated with autologous CAR-T cell therapies developed by major pharmaceutical and biotechnology companies like Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, and Novartis.
• Competitors specifically developing iNKT cell-based therapies, such as Arovella Therapeutics and Brightpath Biotherapeutics, are generally earlier-stage, suggesting MiNK may hold a more advanced position in the clinical development of this specific cell type.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• In 2022, the company received notice of a default judgment from the Belgium Walloon Region Government seeking repayment of approximately $2.5 million of an advance, based on allegations of not providing required notification that research and operations in the region were discontinued.

Related Party Transactions

• Agenus Inc. (former majority stockholder, now beneficially owns approximately 46% of outstanding common stock).
• Amended and Restated Intercompany Services Agreement (effective April 1, 2022) with Agenus, where Agenus provides general and administrative support (financial, facilities, human resources, IT) and both parties provide research and development (R&D) and other support services (legal, regulatory). MiNK pays 10% of Agenus' G&A costs and pass-through plus allocation for R&D services.
• Intellectual Property Assignment and License Agreement (September 2021) with Agenus, assigning certain patent rights and know-how to MiNK and granting MiNK an exclusive, royalty-free, sublicensable license to develop, manufacture, and commercialize certain licensed technology. Agenus retains a field-limited, non-exclusive, royalty-free license under the assigned patent rights.
• A related party note with Agenus, with a principal balance of $5.0 million and accrued interest of approximately $179,444 as of December 31, 2025, was repaid in full in January 2026.
• Due to related parties balance of $15.4 million as of December 31, 2025, which Agenus has agreed not to require repayment of for the foreseeable future.
• Jennifer S. Buell, Ph.D. (President, CEO, and Director of MiNK) is also an employee (Chairman of the Executive Council since January 2023) and director (since June 2024) of Agenus, creating potential conflicts of interest.
• Dr. Buell's spouse is a partner in Wolf, Greenfield & Sachs, P.C., which provided legal services to MiNK totaling approximately $300,000 in 2025 and $168,000 in 2024. Dr. Buell's spouse does not receive direct compensation from these fees, and the fees are an insignificant amount of Wolf Greenfield's revenues; these services were approved by MiNK's Audit and Finance Committee.

Stakeholder Impact

• **Shareholders**: Face dilution risk from ongoing equity raises, potential stock price volatility due to financial performance and market conditions, and the influence of Agenus as a significant stockholder. No dividends are expected in the foreseeable future. The going concern warning indicates a high level of investment risk.
• **Employees**: The company's future success depends on its ability to retain key executives and attract/motivate qualified scientific, clinical, manufacturing, and sales/marketing personnel amidst competition. Expected growth will require expansion of employee base and operational capabilities.
• **Customers/Patients**: Potential for novel iNKT cell therapies to address high unmet medical needs in cancer and immune-mediated diseases, including critical pulmonary immune failure and GvHD. However, the long and uncertain development pathway, potential for adverse events, and regulatory hurdles pose risks to product availability.
• **Creditors**: The company's recurring losses and going concern warning present a risk, although the related party note to Agenus was repaid in January 2026. Future debt financing may be difficult to obtain on commercially reasonable terms.
• **Suppliers/Partners**: Reliance on third-party contract manufacturers and collaborators for clinical trials, preclinical testing, and certain raw materials introduces risks of performance failure, supply disruptions, and non-compliance with regulatory requirements.

Next Steps

• Advance agenT-797 in a randomized Phase 2 adaptive, placebo-controlled trial in patients with severe pneumonia and moderate-to-severe acute hypoxemic respiratory failure (AHRF).
• Continue the Phase 2 investigator-sponsored trial evaluating agenT-797 in combination with Agenus' botensilimab and balstilimab, plus ramucirumab and paclitaxel, for advanced esophageal, gastric, or gastro-esophageal junction (GEJ) adenocarcinoma.
• Expect additional data from the Phase 2 combination study in early 2026.
• Advance Investigational New Drug (IND) enabling studies for MiNK-215 (FAP-CAR-iNKT).
• Build a broad pipeline of engineered iNKT cell therapies, including CARs, TCRs, and iNKT cell engagers.
• Scale manufacturing and operational capabilities to improve scalability, reduce cost of goods, and increase flexibility and speed of production.
• Seek strategic partnerships and collaborations, as well as out-licensing opportunities, for portfolio programs and product candidates.
• Explore avenues for securing non-dilutive financing, such as grants and providing fee-based services.
• Consider potential equity or debt financing options to support liquidity requirements.
• File the definitive proxy statement relating to the 2026 Annual Meeting of Stockholders within 120 days after December 31, 2025.

Key Dates

Recommendation

MiNK Therapeutics presents a high-risk, high-reward profile. The promising early clinical data for agenT-797 in both oncology and critical pulmonary immune failure, coupled with a novel allogeneic iNKT cell platform, offers significant long-term potential. However, the company's recurring operating losses, substantial accumulated deficit, and explicit "going concern" warning from auditors highlight immediate financial instability and a critical need for additional capital. While recent capital raises provide some short-term liquidity, the long and uncertain path to regulatory approval and commercialization, combined with intense competition and reliance on third parties, suggests significant headwinds. A "Hold" recommendation reflects the speculative nature of the investment, acknowledging the potential upside from clinical success while emphasizing the considerable financial and operational risks that could lead to further share price volatility. Investors should monitor future funding efforts and clinical milestones closely.

Keywords

iNKT cell therapy, oncology, immune-mediated diseases, agenT-797, CAR-iNKT, MiNK-215, MiNK-413, allogeneic, off-the-shelf, cancer, ARDS, GvHD, solid tumors, preclinical, clinical trials, biotechnology, biopharmaceutical, SEC filing, 10-K, financial reporting, corporate governance, risk management, Agenus